Prashant Nair is a Mumbai-based Director and Analyst who covers the Indian pharmaceutical, health care and agrochemical sectors for Citi Investment Research.

TWST: Tell me about Dr.Reddy’s (RDY). What is it that you like about them?

Mr. Nair: Dr.Reddy’s is probably one of the best players in the global generics industry in our view, definitely one of the best players among the Indian generic companies. They have a very strong presence in the U.S. and in the Russia-CIS markets. They have a portfolio of products pending approval - not only plain vanilla generic filings, but also a whole lot of patent challenges and limited competition opportunities. So they have products that can help them gain more traction with the trade going forward. It’s a company that is fully integrated in terms of manufacturing, and therefore enjoys the cost advantage that Indian companies have been known for. But at the same time, they have now come to a stage where they have built a certain amount of leverage on the front end in some of the important markets. We think that going forward, this company will potentially grow much faster than most of its competitors in India.

Read more about Prashant Nair’s India Stock Picks in the current Pharmaceuticals Report.

This entry was posted on Sunday, November 8th, 2009 at 9:17 am and is filed under Healthcare Stocks. You can follow any responses to this entry through the RSS 2.0 feed.